Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination with Docetaxel in Participants with Metastatic Castration-resistant Prostate Cancer

    Summary
    EudraCT number
    2021-003990-74
    Trial protocol
    ES   GR  
    Global end of trial date
    13 Dec 2023

    Results information
    Results version number
    v1(current)
    This version publication date
    07 Dec 2024
    First version publication date
    07 Dec 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    CA022-009
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Bristol Myers Squibb
    Sponsor organisation address
    Chaussée de la Hulpe 185, Brussels, Belgium, 1170
    Public contact
    EU Study Start-Up Unit, Bristol-Myers Squibb International Corporation, Clinical.Trials@bms.com
    Scientific contact
    Bristol-Myers Squibb Study Director, Bristol Myers Squibb, Clinical.Trials@bms.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    13 Dec 2023
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    13 Dec 2023
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    To assess the safety, tolerability, and DLTs of docetaxel in combination with BMS-986218 or in combination with BMS-986218 plus nivolumab in participants with mCRPC
    Protection of trial subjects
    The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization Good Clinical Practice Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    14 Feb 2022
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United States: 10
    Worldwide total number of subjects
    10
    EEA total number of subjects
    0
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    4
    From 65 to 84 years
    6
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    10 Participants Enrolled and Treated

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Treatment 1
    Arm description
    BMS-986218 30mg Q3W + Docetaxel 75 mg/m² Q3W
    Arm type
    Experimental

    Investigational medicinal product name
    Docetaxel
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravascular use
    Dosage and administration details
    75 mg/m² Q3W

    Investigational medicinal product name
    BMS-986218
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravascular use
    Dosage and administration details
    30mg Q3W

    Arm title
    Treatment 2
    Arm description
    BMS-986218 50mg Q3W + Docetaxel 75 mg/m² Q3W
    Arm type
    Experimental

    Investigational medicinal product name
    Docetaxel
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravascular use
    Dosage and administration details
    75 mg/m² Q3W

    Investigational medicinal product name
    BMS-986218
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravascular use
    Dosage and administration details
    50mg Q3W

    Number of subjects in period 1
    Treatment 1 Treatment 2
    Started
    3
    7
    Completed
    1
    0
    Not completed
    2
    7
         Participant request to discontinue treatment
    -
    1
         Physician decision
    -
    1
         Adverse event, non-fatal
    1
    3
         Progressive Disease
    1
    1
         Other Reason
    -
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Treatment 1
    Reporting group description
    BMS-986218 30mg Q3W + Docetaxel 75 mg/m² Q3W

    Reporting group title
    Treatment 2
    Reporting group description
    BMS-986218 50mg Q3W + Docetaxel 75 mg/m² Q3W

    Reporting group values
    Treatment 1 Treatment 2 Total
    Number of subjects
    3 7 10
    Age categorical
    Units: Subjects
        Adults (18-64 years)
    1 3 4
        From 65-84 years
    2 4 6
    Age Continuous
    Units: Years
        arithmetic mean (standard deviation)
    68.3 ( 6.11 ) 65.7 ( 9.14 ) -
    Sex: Female, Male
    Units: Participants
        Female
    0 0 0
        Male
    3 7 10
    Race (NIH/OMB)
    Units: Subjects
        American Indian or Alaska Native
    0 0 0
        Asian
    0 0 0
        Native Hawaiian or Other Pacific Islander
    0 0 0
        Black or African American
    0 0 0
        White
    3 6 9
        More than one race
    0 0 0
        Unknown or Not Reported
    0 1 1
    Ethnicity (NIH/OMB)
    Units: Subjects
        Hispanic or Latino
    1 0 1
        Not Hispanic or Latino
    2 6 8
        Unknown or Not Reported
    0 1 1

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Treatment 1
    Reporting group description
    BMS-986218 30mg Q3W + Docetaxel 75 mg/m² Q3W

    Reporting group title
    Treatment 2
    Reporting group description
    BMS-986218 50mg Q3W + Docetaxel 75 mg/m² Q3W

    Primary: Number of Participants with Treatment related Adverse Events

    Close Top of page
    End point title
    Number of Participants with Treatment related Adverse Events [1]
    End point description
    Adverse events will presetned using National Cancer Institute Common Terminology Criteria for Adverse Events version 5 (NCI CTCAE v5).
    End point type
    Primary
    End point timeframe
    From first dose to 100 days follow up to last dose (Approximately 22 months)
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis done for this endpoint
    End point values
    Treatment 1 Treatment 2
    Number of subjects analysed
    3
    7
    Units: Participants
    3
    7
    No statistical analyses for this end point

    Primary: Number of Participants with Treatment related Serious Adverse Events

    Close Top of page
    End point title
    Number of Participants with Treatment related Serious Adverse Events [2]
    End point description
    Adverse events will presetned using National Cancer Institute Common Terminology Criteria for Adverse Events version 5 (NCI CTCAE v5).
    End point type
    Primary
    End point timeframe
    From first dose to 100 days follow up to last dose (Approximately 22 months)
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis done for this endpoint
    End point values
    Treatment 1 Treatment 2
    Number of subjects analysed
    3
    7
    Units: Participants
    1
    4
    No statistical analyses for this end point

    Primary: Number of Participants with Dose Limiting Toxicities

    Close Top of page
    End point title
    Number of Participants with Dose Limiting Toxicities [3]
    End point description
    DLTs will be definied as: Any treatment-related AEs for which a participant permanently discontinues a study treatment (other than daily prednisone) and that occurs during the first 2 cycles of treatment. Any death not clearly due to the underlying disease or extraneous causes and that occurs during the first 2 cycles of treatment Greater than or equal to Grade 2 pneumonitis lasting greater than 5 days despite appropriate medical therapy and that occurs during the first 2 cycles of treatment Any neutropenic fever as well as Grade 4 neutropenia or thrombocytopenia for > 7 days that occurs during the first 2 cycles of treatment Any treatment-related AE that delays initiation of Cycle 2 or Cycle 3 of treatment by greater than 2 consecutive weeks.
    End point type
    Primary
    End point timeframe
    From first dose to 100 days follow up to last dose (Approximately 22 months)
    Notes
    [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis done for this endpoint
    End point values
    Treatment 1 Treatment 2
    Number of subjects analysed
    3
    7
    Units: Participants
    1
    0
    No statistical analyses for this end point

    Primary: Number of Participants with AEs leading to discontinuation

    Close Top of page
    End point title
    Number of Participants with AEs leading to discontinuation [4]
    End point description
    Adverse events will presetned using National Cancer Institute Common Terminology Criteria for Adverse Events version 5 (NCI CTCAE v5).
    End point type
    Primary
    End point timeframe
    From first dose to 100 days follow up to last dose (Approximately 22 months)
    Notes
    [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis done for this endpoint
    End point values
    Treatment 1 Treatment 2
    Number of subjects analysed
    3
    7
    Units: Participants
    2
    4
    No statistical analyses for this end point

    Primary: Number of Participants who died

    Close Top of page
    End point title
    Number of Participants who died [5]
    End point description
    Number of participant deaths
    End point type
    Primary
    End point timeframe
    From first dose to 100 days follow up to last dose (Approximately 22 months)
    Notes
    [5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis done for this endpoint
    End point values
    Treatment 1 Treatment 2
    Number of subjects analysed
    3
    7
    Units: Participants
    2
    2
    No statistical analyses for this end point

    Secondary: Objective Response Rate

    Close Top of page
    End point title
    Objective Response Rate
    End point description
    Objective response rate per PCWG3 (ORR-PCWG3) is the proportion of participants who have a confirmed complete or partial best overall response (BOR) per PCWG3 among randomized participants who have measurable disease at baseline. The BOR is defined as the best response designation, as determined by the BICR, recorded between the date of randomization and the date of objectively documented radiographic progression, or last tumor measurement, whichever occurs first.
    End point type
    Secondary
    End point timeframe
    From first dose to 100 days follow up to last dose (Approximately 22 months)
    End point values
    Treatment 1 Treatment 2
    Number of subjects analysed
    0 [6]
    0 [7]
    Units: Percentage of Participants
        number (confidence interval 95%)
    ( to )
    ( to )
    Notes
    [6] - No subjects Analyzed for this endpoint
    [7] - No subjects Analyzed for this endpoint
    No statistical analyses for this end point

    Secondary: Prostate Specific Antigen Response Rate (PSA-RR)

    Close Top of page
    End point title
    Prostate Specific Antigen Response Rate (PSA-RR)
    End point description
    PSA-RR is the proportion of randomized participants with a 50% or greater decrease in PSA from baseline to any post-baseline PSA result. A second consecutive value obtained 3 or more weeks later is required to confirm the PSA response.
    End point type
    Secondary
    End point timeframe
    From first dose to 100 days follow up to last dose (Approximately 22 months)
    End point values
    Treatment 1 Treatment 2
    Number of subjects analysed
    3
    7
    Units: Percentage of Participants
    number (confidence interval 95%)
        Unconfirmed or Confirmed PSA responders
    33.3 (0.8 to 90.6)
    57.1 (18.4 to 90.1)
        Confirmed PSA responders
    33.3 (0.8 to 90.6)
    57.1 (18.4 to 90.1)
    No statistical analyses for this end point

    Secondary: Duration of Response

    Close Top of page
    End point title
    Duration of Response
    End point description
    Duration of response per PCWG3 (DOR-PCWG3) is the time between the date of first response (CR/PR per PCWG3) to the date of first documented radiographic progression per PCWG3 (as determined by BICR), or death due to any cause.
    End point type
    Secondary
    End point timeframe
    From first dose to 100 days follow up to last dose (Approximately 22 months)
    End point values
    Treatment 1 Treatment 2
    Number of subjects analysed
    0 [8]
    0 [9]
    Units: Months
        median (full range (min-max))
    ( to )
    ( to )
    Notes
    [8] - No subjects Analyzed for this endpoint
    [9] - No subjects Analyzed for this endpoint
    No statistical analyses for this end point

    Secondary: Time to Response

    Close Top of page
    End point title
    Time to Response
    End point description
    Time to response per PCWG3 (TTR-PCWG3) is the time from randomization date to the date of the first documented CR or PR per PCWG3, as determined by BICR.
    End point type
    Secondary
    End point timeframe
    From first dose to 100 days follow up to last dose (Approximately 22 months)
    End point values
    Treatment 1 Treatment 2
    Number of subjects analysed
    0 [10]
    0 [11]
    Units: Months
        median (full range (min-max))
    ( to )
    ( to )
    Notes
    [10] - No subjects Analyzed for this endpoint
    [11] - No subjects Analyzed for this endpoint
    No statistical analyses for this end point

    Secondary: Overall Survival

    Close Top of page
    End point title
    Overall Survival
    End point description
    OS for all randomized participants is the time between randomization date and the date of death from any cause.
    End point type
    Secondary
    End point timeframe
    From first dose to 100 days follow up to last dose (Approximately 22 months)
    End point values
    Treatment 1 Treatment 2
    Number of subjects analysed
    0 [12]
    0 [13]
    Units: Percentage of Participants
        number (confidence interval 95%)
    ( to )
    ( to )
    Notes
    [12] - No subjects Analyzed for this endpoint
    [13] - No subjects Analyzed for this endpoint
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Adverse Events and Serious Adverse Events: (From first dose to last dose + 100 days): Approximately 22 Months All-Cause mortality (From randomization to end of study): Approximately 22 Months.
    Adverse event reporting additional description
    The number at Risk for All-Cause Mortality represents all Randomized Participants. The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    26.1
    Reporting groups
    Reporting group title
    Treatment 1
    Reporting group description
    BMS-986218 30mg Q3W + Docetaxel 75 mg/m² Q3W

    Reporting group title
    Treatment 2
    Reporting group description
    BMS-986218 50mg Q3W + Docetaxel 75 mg/m² Q3W

    Serious adverse events
    Treatment 1 Treatment 2
    Total subjects affected by serious adverse events
         subjects affected / exposed
    1 / 3 (33.33%)
    6 / 7 (85.71%)
         number of deaths (all causes)
    2
    2
         number of deaths resulting from adverse events
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Malignant neoplasm progression
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Injury, poisoning and procedural complications
    Fall
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vascular disorders
    Vasculitis
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypotension
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Shock haemorrhagic
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorders
    Metabolic encephalopathy
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Syncope
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal haemorrhage
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Enterocolitis
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Small intestinal obstruction
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Small intestinal haemorrhage
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Pulmonary embolism
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal and urinary disorders
    Acute kidney injury
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Rectal abscess
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Enterocolitis infectious
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    1 / 3 (33.33%)
    3 / 7 (42.86%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Treatment 1 Treatment 2
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    3 / 3 (100.00%)
    7 / 7 (100.00%)
    Vascular disorders
    Orthostatic hypotension
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Hypotension
         subjects affected / exposed
    0 / 3 (0.00%)
    5 / 7 (71.43%)
         occurrences all number
    0
    11
    Hypertension
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 7 (14.29%)
         occurrences all number
    1
    1
    Hot flush
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 7 (28.57%)
         occurrences all number
    0
    2
    Flushing
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 7 (14.29%)
         occurrences all number
    1
    1
    Chills
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    2
    Face oedema
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Fatigue
         subjects affected / exposed
    3 / 3 (100.00%)
    4 / 7 (57.14%)
         occurrences all number
    3
    4
    Generalised oedema
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Influenza like illness
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    2
    Pyrexia
         subjects affected / exposed
    0 / 3 (0.00%)
    4 / 7 (57.14%)
         occurrences all number
    0
    5
    Oedema peripheral
         subjects affected / exposed
    1 / 3 (33.33%)
    3 / 7 (42.86%)
         occurrences all number
    1
    3
    Mucosal inflammation
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    6
    0
    Malaise
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 7 (14.29%)
         occurrences all number
    1
    1
    Localised oedema
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 7 (14.29%)
         occurrences all number
    1
    1
    Injection site reaction
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Swelling face
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Terminal agitation
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Immune system disorders
    Drug hypersensitivity
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    4
    0
    Hypersensitivity
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    2
    Respiratory, thoracic and mediastinal disorders
    Pulmonary oedema
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Pleural effusion
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Oropharyngeal pain
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Laryngeal inflammation
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Epistaxis
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Dyspnoea exertional
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Dyspnoea
         subjects affected / exposed
    1 / 3 (33.33%)
    2 / 7 (28.57%)
         occurrences all number
    1
    2
    Cough
         subjects affected / exposed
    1 / 3 (33.33%)
    2 / 7 (28.57%)
         occurrences all number
    2
    2
    Sleep apnoea syndrome
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Rhinorrhoea
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Respiratory failure
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Psychiatric disorders
    Insomnia
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Depression
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Confusional state
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Investigations
    Lymphocyte count decreased
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Alanine aminotransferase increased
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    3
    Influenza A virus test positive
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Blood thyroid stimulating hormone increased
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Blood lactate dehydrogenase increased
         subjects affected / exposed
    1 / 3 (33.33%)
    2 / 7 (28.57%)
         occurrences all number
    1
    2
    Blood creatinine increased
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 7 (14.29%)
         occurrences all number
    2
    2
    Blood alkaline phosphatase increased
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Aspartate aminotransferase increased
         subjects affected / exposed
    1 / 3 (33.33%)
    2 / 7 (28.57%)
         occurrences all number
    1
    2
    Mycobacterium tuberculosis complex test positive
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Neutrophil count decreased
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 7 (28.57%)
         occurrences all number
    0
    2
    Nitrite urine present
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Platelet count decreased
         subjects affected / exposed
    2 / 3 (66.67%)
    1 / 7 (14.29%)
         occurrences all number
    2
    2
    Prostatic specific antigen increased
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Weight increased
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    2
    White blood cell count decreased
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 7 (14.29%)
         occurrences all number
    1
    2
    Injury, poisoning and procedural complications
    Fall
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 7 (14.29%)
         occurrences all number
    1
    1
    Infusion related reaction
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 7 (14.29%)
         occurrences all number
    1
    1
    Procedural pain
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Nervous system disorders
    Dizziness
         subjects affected / exposed
    0 / 3 (0.00%)
    3 / 7 (42.86%)
         occurrences all number
    0
    3
    Dysgeusia
         subjects affected / exposed
    1 / 3 (33.33%)
    3 / 7 (42.86%)
         occurrences all number
    1
    3
    Syncope
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    2
    Somnolence
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Presyncope
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Headache
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Neuropathy peripheral
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 7 (14.29%)
         occurrences all number
    1
    1
    Paraesthesia
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Peripheral sensory neuropathy
         subjects affected / exposed
    1 / 3 (33.33%)
    2 / 7 (28.57%)
         occurrences all number
    1
    2
    Blood and lymphatic system disorders
    Blood loss anaemia
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Anaemia
         subjects affected / exposed
    1 / 3 (33.33%)
    4 / 7 (57.14%)
         occurrences all number
    1
    4
    Ear and labyrinth disorders
    Tinnitus
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Eye disorders
    Eye disorder
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Gastrointestinal disorders
    Abdominal distension
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Constipation
         subjects affected / exposed
    1 / 3 (33.33%)
    2 / 7 (28.57%)
         occurrences all number
    1
    3
    Colitis
         subjects affected / exposed
    1 / 3 (33.33%)
    4 / 7 (57.14%)
         occurrences all number
    1
    5
    Bowel movement irregularity
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Ascites
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Abdominal pain
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Vomiting
         subjects affected / exposed
    0 / 3 (0.00%)
    3 / 7 (42.86%)
         occurrences all number
    0
    4
    Proctitis
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 7 (28.57%)
         occurrences all number
    0
    2
    Oral pain
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Nausea
         subjects affected / exposed
    1 / 3 (33.33%)
    5 / 7 (71.43%)
         occurrences all number
    1
    8
    Mouth ulceration
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Lower gastrointestinal haemorrhage
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Haemorrhoids
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Haemorrhoidal haemorrhage
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 7 (28.57%)
         occurrences all number
    0
    2
    Haematochezia
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 7 (14.29%)
         occurrences all number
    1
    1
    Gastrointestinal haemorrhage
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Enterocolitis
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Dysphagia
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Diarrhoea
         subjects affected / exposed
    3 / 3 (100.00%)
    4 / 7 (57.14%)
         occurrences all number
    3
    11
    Skin and subcutaneous tissue disorders
    Skin ulcer
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 7 (14.29%)
         occurrences all number
    1
    1
    Skin exfoliation
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Skin disorder
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Rash maculo-papular
         subjects affected / exposed
    1 / 3 (33.33%)
    3 / 7 (42.86%)
         occurrences all number
    1
    3
    Rash macular
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Rash
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Pruritus
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Night sweats
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Nail discolouration
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Erythema
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Alopecia
         subjects affected / exposed
    2 / 3 (66.67%)
    3 / 7 (42.86%)
         occurrences all number
    2
    3
    Skin hyperpigmentation
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Renal and urinary disorders
    Urethral pain
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Proteinuria
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Haematuria
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Cystitis noninfective
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Acute kidney injury
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Endocrine disorders
    Hypothyroidism
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    2
    Adrenal insufficiency
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    0 / 3 (0.00%)
    3 / 7 (42.86%)
         occurrences all number
    0
    3
    Back pain
         subjects affected / exposed
    2 / 3 (66.67%)
    0 / 7 (0.00%)
         occurrences all number
    2
    0
    Bone pain
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Muscular weakness
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 7 (28.57%)
         occurrences all number
    0
    2
    Neck pain
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Pain in extremity
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Sacral pain
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Infections and infestations
    COVID-19
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Candida infection
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    5
    Cellulitis
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Rectal abscess
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Sinusitis
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Staphylococcal skin infection
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Submandibular abscess
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    2
    Tooth infection
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Upper respiratory tract infection
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Urinary tract infection
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    1 / 3 (33.33%)
    2 / 7 (28.57%)
         occurrences all number
    1
    3
    Dehydration
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 7 (14.29%)
         occurrences all number
    2
    1
    Hypercalcaemia
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Hyperglycaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Hypermagnesaemia
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 7 (0.00%)
         occurrences all number
    1
    0
    Hyperphosphataemia
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 7 (14.29%)
         occurrences all number
    0
    1
    Hypoalbuminaemia
         subjects affected / exposed
    1 / 3 (33.33%)
    2 / 7 (28.57%)
         occurrences all number
    1
    2
    Hypocalcaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 7 (28.57%)
         occurrences all number
    0
    3
    Hypokalaemia
         subjects affected / exposed
    1 / 3 (33.33%)
    3 / 7 (42.86%)
         occurrences all number
    1
    8
    Hypomagnesaemia
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 7 (14.29%)
         occurrences all number
    1
    3
    Hyponatraemia
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 7 (28.57%)
         occurrences all number
    0
    3
    Hypophosphataemia
         subjects affected / exposed
    0 / 3 (0.00%)
    4 / 7 (57.14%)
         occurrences all number
    0
    6

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    18 Feb 2022
    The overall purpose for Protocol Amendment 02 is to introduce information regarding BMS- 986288, an additional “next-generation” anti-cytotoxic T-lymphocyte-associated protein 4 (anti- CTLA-4) monoclonal antibody (mAb). BMS-986288 may be incorporated into the study design via future protocol amendment to test further the central study hypothesis that addition of nextgeneration anti-CTLA-4 agents, with or without nivolumab, will improve outcomes compared to docetaxel alone. BMS-986288 is another non-fucosylated next-generation anti-CTLA-4 that shares the Fcγ receptor (FcγR)-dependent mechanisms of BMS-986218. BMS-986288 is identical to BMS-986218 except for an additional “Probody” design element that could decrease toxicity by preventing binding to sites outside of the tumor, and thus further improve the benefit/risk profile as compared to BMS-986218. An update was also made to the Bayesian Optimal Interval (BOIN) table that eliminated criteria for 1 or 2 participants, as enrollment will be in groups of 3 to 4 participants at a time in Part 1a and Part 1b.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    This study was terminated early after the safety lead-in portion (Part 1).
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 18:05:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA